Intellipharmaceutics International Inc. (IPCI)

[fabius]

Angelo,
I'm reading SEC filings of the IPCI competitors.

Among various interesting aspetcs I have found under the last Egalet 10Q a very good example of Licensing Agreement (which was by the way terminated in 2015).

Considering the early stage of products development when it was signed (2013) the structure reinforces what you several times proposed on this board. If we make a comparison with IPCI current stage of process....

Take a look
"Under the terms of the Shionogi Agreement, the Company received an upfront payment of $10.0 million in 2013 and payment of $10.0 million in April 2015 upon submission of an Investigational New Drug (“IND”) application by Shionogi. The Company was eligible to receive regulatory milestone payments under the agreement as follows:
(i) an additional $50.0 million upon successful achievement of specified regulatory milestones for the first licensed product
candidate;
(ii) up to $42.5 million upon successful achievement of specified regulatory milestones for a defined combination product candidate;
(iii) up to $25.0 million upon successful achievement of specified regulatory milestones for a second product candidate (other than the defined combination product candidate);
and (iv) up to $12.5 million upon successful achievement of specified regulatory milestones for further product candidates.

In addition, the Company was eligible to receive up to an aggregate of $185.0 million based on successful achievement of specified net sales thresholds of licensed products.